-------------------------------------------------------------------------
Weighted average
number of common
shares 38,245,559 37,974,433 38,192,419 37,973,848
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Basic and diluted
loss per share (0.16) (0.16) (0.32) (0.25)
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Consolidated Statement of Cash Flows (unaudited)
Three Months Three Months Six Months Six Months
Ended March Ended March Ended March Ended March
31, 2008 31, 2007 31, 2008 31, 2007
$ $ $ $
OPERATING ACTIVITIES
Net loss and other
comprehensive
loss for the
period (6,063,584) (6,026,043) (12,179,267) (9,564,607)
Items not
affecting cash
Stock-based
compensation
expense 509,498 395,934 1,036,957 769,756
Interest
capitalized on
long-term debt - 571,013 - 1,140,355
Amortization of
intellectual
property 64,275 514,265 127,502 974,417
Amortization of
consoles at
customers' premises 221,747 269,474 440,470 478,312
Amortization of
property, plant,
and equipment 401,844 438,399 793,478 646,407
Amortization of
deferred financing
charges 102,427 118,705 205,888 258,698
Unrealized (gain)
'/>"/>
| SOURCE CryoCath Technologies Inc. Copyright©2008 PR Newswire. All rights reserved |